R&D | December 22, 2025
Xeureka & UBE launch joint cancer drug discovery program
Xeureka will receive an upfront payment from UBE and will be eligible for milestone payments tied to future research progress
Xeureka will receive an upfront payment from UBE and will be eligible for milestone payments tied to future research progress
Efdoralprin alfa, a recombinant human alpha-1 antitrypsin (AAT)-Fc fusion protein, showed superior efficacy to standard plasma-derived therapy in adults with AATD
SandboxAQ will receive an upfront payment and could earn up to $200 million in milestone payments tied to preclinical, development, regulatory, and commercial achievements
The multi-partner team will integrate new technologies across the entire mAb production workflow, from cell line development to purification
The U.S. oncology market is projected to soar from $81 billion in 2025 to $212 billion by 2034
The approval follows strong results from Roche’s phase II NOBILITY and phase III REGENCY studies
Golcadomide, a CELMoD agent, continued to deliver deep and durable responses in aggressive B-cell and follicular lymphomas
The agreement pairs Croda’s global footprint and “smart science” approach with Amino’s precision manufacturing capabilities
Alport Syndrome is caused by genetic mutations affecting type IV collagen in the kidneys, ears, and eyes
Jacobio stated that these findings underscore the potential of glecirasib and sitneprotafib
Subscribe To Our Newsletter & Stay Updated
